Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
5.90M | 8.26M | 8.25M | 7.38M | 9.27M | Gross Profit |
3.95M | 5.75M | 5.92M | 5.25M | 2.25M | EBIT |
-7.15M | -4.74M | -2.28M | -2.09M | -11.53M | EBITDA |
-7.10M | -4.69M | -2.21M | -2.00M | -8.79M | Net Income Common Stockholders |
-6.53M | -4.37M | -2.21M | -2.00M | -3.65M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
18.00M | 21.20M | 22.57M | 5.23M | 3.13M | Total Assets |
21.42M | 24.67M | 24.89M | 7.99M | 6.89M | Total Debt |
240.88K | 355.91K | 306.71K | 461.41K | 916.67K | Net Debt |
-1.49M | -3.90M | -22.27M | -4.76M | -2.21M | Total Liabilities |
1.33M | 1.31M | 1.67M | 2.75M | 4.36M | Stockholders Equity |
20.09M | 23.36M | 23.22M | 5.25M | 2.53M |
Cash Flow | Free Cash Flow | |||
-6.27M | -5.31M | -2.21M | -2.07M | -3.67M | Operating Cash Flow |
-6.08M | -5.29M | -2.07M | -2.07M | -3.62M | Investing Cash Flow |
1.16M | -16.89M | -131.71K | 0.00 | -48.08K | Financing Cash Flow |
2.33M | 3.86M | 19.55M | 4.17M | 15.11K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $10.97M | ― | -114.22% | ― | 0.61% | 16.43% | |
52 Neutral | $5.36B | 3.88 | -42.93% | 2.87% | 17.85% | 1.45% | |
45 Neutral | $9.43M | ― | -45.38% | ― | -48.61% | 32.18% | |
45 Neutral | $9.81M | ― | -72.70% | ― | 5.05% | 26.13% | |
44 Neutral | $7.32M | ― | -405.19% | ― | 11.92% | 87.83% | |
42 Neutral | $6.97M | ― | -174.07% | ― | 9.90% | 94.56% | |
40 Underperform | $5.64M | ― | -662.74% | ― | ― | -10.29% |
Neurometrix has undergone a significant corporate restructuring through a merger agreement, resulting in the cancellation and conversion of its common and preferred stock into cash and contingent value rights (CVRs). The merger, effective as of May 2, 2025, also led to the delisting of its common stock from Nasdaq and changes in its board and executive leadership, with new directors and executives appointed from the merger partner’s team.
Spark’s Take on NURO Stock
According to Spark, TipRanks’ AI Analyst, NURO is a Neutral.
Neurometrix’s overall stock score is primarily impacted by its weak financial performance marked by declining revenues and persistent losses. While technical indicators show some positive momentum, the stock’s unattractive valuation, due to its negative earnings and lack of dividends, further drags down the score. Improvement in financial health and sustainable profitability are essential for a better outlook.
To see Spark’s full report on NURO stock, click here.